SAN DIEGO, July 24, 2001 (PRIMEZONE) -- Women First HealthCare, Inc. (Nasdaq:WFHC) said that on Thursday, July 26, 2001 the Company will release its financial results for the second quarter and six months ended June 30, 2001. Edward F. Calesa, chairman, president and CEO, and Charles M. Caporale, vice president and CFO, will host a conference call that same day at 11 a.m. Eastern Time (8 a.m. Pacific Time) to discuss the Company's financial results. Discussions may contain forward-looking and other material information.
Access Instructions:
The July 26 conference call will be available to all interested parties through a live audio Web broadcast via the Internet at Women First's Website, www.womenfirst.com, and at www.streetfusion.com.
Replay Option Available Until August 9, 2001:
Audio-only via Internet: The call will be archived and available on the above Websites for two weeks beginning 1 p.m., EST, Thursday, July 26, through 5 p.m., EST, Thursday, August 9.
Audio-only via Telephone: A telephone replay of the call will also be available from 1 p.m., EST, Thursday, July 26, through 5 p.m., EST, Thursday, August 9. Please call (888) 203-1112 (domestic) or (719) 457-0820 (international) and use access code No. 585883.
For further information please contact Diane Donohue, Manager, Public Relations, Women First HealthCare, Inc., (858) 509-3860, ddonohue@womenfirst.com or Tom Jackson/Dian Griesel at The Investor Relations Group, Inc. (212) 825-3210.
About Women First HealthCare, Inc.
Founded in 1996, Women First HealthCare, Inc. is a San Diego-based specialty pharmaceutical company. Its mission is to help midlife women make informed choices regarding their health care needs and to provide pharmaceutical and lifestyle products to meet those needs. Women First is specifically targeted to women age 40+ and their clinicians. The Company's Pharmaceutical Division, which includes a nationwide team of experienced sales specialists, contacts primarily OB/GYNs and Nurse Practitioners with estrogen replenishment options -- ORTHO-EST(r) Tablets (estropipate) and Esclim(tm) (estradiol transdermal system) -- and the prescription headache management product, Midrin(r) (isometheptene mucate, USP, dichloralphenazone, USP and acetaminophen, USP). The Consumer Business is responsible for Daily Difference(tm) dietary supplements, developed in consultation with Tufts University School of Nutrition Science and Policy, and the Company's line of self-care products available through its As We Change(r) national mail order catalog and Internet retailer, www.aswechange.com. Trialogue(tm), the Corporate Marketing Division, is responsible for providing access to Women First's network of opinion leaders and clinicians through strategic marketing programs for sale to major pharmaceutical companies. The Company's business strategy includes the acquisition and licensing of additional prescription products that support its mission. Further information about Women First can be found online at www.womenfirst.com.